Effexor (venlafaxine) and Cymbalta (duloxetine) are the two most commonly prescribed SNRIs. They have similar efficacy in generalized anxiety and depression. Venlafaxine has more dose flexibility at lower doses and a more pronounced discontinuation syndrome; duloxetine has stronger indications in chronic pain conditions and a more even dose-response profile. The choice often comes down to specific patient factors.
The short version
Both are SNRIs with substantial evidence in generalized anxiety and depression. The Effexor reference and the Cymbalta reference cover each drug in detail; this page focuses on the head-to-head. The class context is in SNRIs explained.
How they differ
Mechanism details
Both block reuptake of serotonin and norepinephrine. The serotonin-to-norepinephrine ratio differs by dose:
- Venlafaxine is predominantly serotonergic at doses under about 150 mg and progressively more noradrenergic above that.
- Duloxetine has a more balanced serotonin-norepinephrine effect across the dose range.
The clinical relevance is that low-dose venlafaxine (75 mg) functionally resembles an SSRI, while higher-dose venlafaxine adds the norepinephrine effect (and the dose-related blood pressure consideration). Duloxetine produces the norepinephrine effect at standard starting doses. For the shared mechanism in motion, see how SNRIs act on the synapse, animated by PsychiatryRx.
Indications
Venlafaxine is FDA-approved for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.
Duloxetine is FDA-approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain.
For a patient with co-occurring anxiety and chronic pain, duloxetine is often the cleaner single-drug solution. For a patient with social anxiety or panic disorder, venlafaxine has more anxiety-specific FDA approvals. The MedlinePlus venlafaxine page and the MedlinePlus duloxetine page are good consumer references.
Blood pressure
Venlafaxine produces a small dose-related rise in blood pressure that becomes clinically relevant above about 150 mg daily. Patients with existing hypertension should have it monitored after starting and after dose increases.
Duloxetine has less blood pressure effect, though small changes are still possible.
Discontinuation syndrome
Both have short half-lives and a notable discontinuation syndrome with abrupt stopping or missed doses: dizziness, electric-shock sensations, flu-like symptoms, irritability. Venlafaxine's discontinuation syndrome is often described as more difficult, requiring tapers over weeks to months. Duloxetine's is also significant but somewhat more manageable.
Side effects
Both can cause nausea, sweating, sexual dysfunction, sleep disruption, and dry mouth. Nausea is somewhat more prominent with duloxetine; sweating somewhat more prominent with venlafaxine.
Liver considerations
Duloxetine has caution language for patients with significant liver disease and is generally avoided in patients with substantial daily alcohol intake. Venlafaxine has fewer liver-specific concerns.
Dosing
Venlafaxine XR: starting 37.5 to 75 mg, target 75 to 225 mg, once daily.
Duloxetine: starting 30 mg, target 60 to 120 mg, once daily.
When to choose Effexor
- Generalized anxiety or panic disorder where SSRIs haven't produced enough response
- Patients with social anxiety where SNRI evidence matters
- Patients where the dose flexibility at low doses (functional SSRI-like behavior) is useful
- Patients without hypertension where higher-dose norepinephrine effect may help
When to choose Cymbalta
- Patient with co-occurring anxiety and depression and chronic pain (fibromyalgia, diabetic neuropathy, chronic musculoskeletal pain)
- Patient with hypertension where Effexor's blood pressure effect is a concern
- Patient who needs the analgesic effect alongside the antidepressant effect
What both have in common
- Four to six week therapeutic timeline at a stable dose
- FDA boxed warning on increased suicidal ideation in patients under 25 in the first weeks
- Sexual side effects are common across both
- Significant discontinuation syndrome requires gradual taper
- Not controlled substances; no addiction risk
- Sweating is more common than with SSRIs and can be persistent
For patients who don't respond to either SNRI, the next steps depend on the case and might include returning to an SSRI from a different chemical family, adding augmentation, or reconsidering the diagnosis. The NIMH anxiety disorders overview describes the broader treatment landscape.